Xenon Pharmaceuticals Stock Return On Asset
| XENE Stock | USD 42.12 0.51 1.20% |
Xenon Pharmaceuticals fundamentals help investors to digest information that contributes to Xenon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Xenon Stock. The fundamental analysis module provides a way to measure Xenon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xenon Pharmaceuticals stock.
As of December 2, 2024, Return On Assets is expected to decline to -0.2. Xenon | Return On Asset |
Xenon Pharmaceuticals Company Return On Asset Analysis
Xenon Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Xenon Pharmaceuticals Return On Asset | -0.19 |
Most of Xenon Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xenon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Xenon Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Xenon Pharmaceuticals is extremely important. It helps to project a fair market value of Xenon Stock properly, considering its historical fundamentals such as Return On Asset. Since Xenon Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Xenon Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Xenon Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Xenon Total Assets
Total Assets |
|
Based on the latest financial disclosure, Xenon Pharmaceuticals has a Return On Asset of -0.1892. This is 97.84% lower than that of the Biotechnology sector and 99.2% lower than that of the Health Care industry. The return on asset for all United States stocks is 35.14% higher than that of the company.
Xenon Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xenon Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xenon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xenon Pharmaceuticals by comparing valuation metrics of similar companies.Xenon Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Xenon Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Xenon Pharmaceuticals from analyzing Xenon Pharmaceuticals' financial statements. These drivers represent accounts that assess Xenon Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Xenon Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 340.1M | 531.3M | 1.4B | 2.4B | 2.1B | 2.3B | |
| Enterprise Value | 331.8M | 489.6M | 1.2B | 2.3B | 2.1B | 2.2B |
Xenon Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Xenon Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Xenon Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Xenon Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 2.61 B | ||||
| Shares Outstanding | 76.24 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 99.63 % | ||||
| Number Of Shares Shorted | 2.94 M | ||||
| Price To Earning | (1.75) X | ||||
| Price To Book | 4.07 X | ||||
| Price To Sales | 181.44 X | ||||
| Gross Profit | (96.33 M) | ||||
| EBITDA | (210.51 M) | ||||
| Net Income | (182.39 M) | ||||
| Cash And Equivalents | 788.24 M | ||||
| Cash Per Share | 12.66 X | ||||
| Total Debt | 10.9 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 57.86 X | ||||
| Book Value Per Share | 12.31 X | ||||
| Cash Flow From Operations | (145.33 M) | ||||
| Short Ratio | 7.75 X | ||||
| Earnings Per Share | (2.81) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 57.18 | ||||
| Number Of Employees | 251 | ||||
| Beta | 1.25 | ||||
| Market Capitalization | 3.29 B | ||||
| Total Asset | 964.8 M | ||||
| Retained Earnings | (665.14 M) | ||||
| Working Capital | 617.69 M | ||||
| Current Asset | 60.87 M | ||||
| Current Liabilities | 2.78 M | ||||
| Net Asset | 964.8 M |
About Xenon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xenon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xenon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xenon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:Check out Xenon Pharmaceuticals Piotroski F Score and Xenon Pharmaceuticals Altman Z Score analysis. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.81) | Quarterly Revenue Growth (1.00) | Return On Assets (0.19) | Return On Equity (0.27) |
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.